BeiGene Puts Up $10M to Use Ambrx?s Drug Development Technology

Chinese pharma company BeiGene has agreed to pay Ambrx $10 million upfront to experiment with technology the biotech has developed in a bid accelerate BeiGene?s search for new protein drugs for cancer treatment. Ambrx says its technology is able to incorporate ?non-natural? amino acids into cells like E. coli and CHO, two cell lines commonly [?]